Lijuan J. Jiang

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

YAP1 lactylation confers cisplatin resistance and prognostic value by suppressing ferroptosis via FOSL1 in bladder cancer.

YAP1 lactylation confers cisplatin resistance and prognostic value by suppressing ferroptosis via FOSL1 in bladder cancer.

Journal: Cell reports

Published: March 09, 2026

Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial.

Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial.

Journal: BMC medicine

Published: November 21, 2025

Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer.

Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer.

Journal: Cancer cell

Published: August 11, 2025

Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance.

Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance.

Journal: International immunopharmacology

Published: April 24, 2025

Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study.

Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study.

Journal: Cancer medicine

Published: October 24, 2024

AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity.

AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity.

Journal: Cell reports

Published: August 22, 2024

Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.

Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 25, 2024

First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study.

First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 19, 2024

GPNMB and ATP6V1A interact to mediate microglia phagocytosis of multiple types of pathological particles.

GPNMB and ATP6V1A interact to mediate microglia phagocytosis of multiple types of pathological particles.

Journal: Cell reports

Published: March 07, 2024

Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma

Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: August 14, 2023

Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial.

Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial.

Journal: Cell reports. Medicine

Published: February 27, 2023

Efficacy and safety of neoadjuvant toripalimab combined with nimotuzumab and chemotherapy in patients with unresectable stage Ⅳ squamous cell carcinoma of penis

Efficacy and safety of neoadjuvant toripalimab combined with nimotuzumab and chemotherapy in patients with unresectable stage Ⅳ squamous cell carcinoma of penis

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: December 08, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026